Elvia Cowan, SVP, Finance & CAO at Vaxcyte, Inc. (PCVX), sold 3,784 shares at $55.39 ($210K) on 2026-03-17, disclosed to the SEC on 2026-03-18.
Scheduled sale ($210k) by SVP, Finance & CAO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $55.39 | 1,487 | $82K | 39.2% |
| 2 | $55.39 | 1,487 | $82K | 39.2% |
| 3 | $56.26 | 405 | $23K | 10.8% |
| 4 | $56.26 | 405 | $23K | 10.8% |
| Total | $55.58 avg | 3,784 | $210K | 100% |
| Filing → |
| PCVX | SELL | 2026-03-11 | $293K | — | Filing → |
| PCVX | SELL | 2025-12-29 | $1.1M | — | Filing → |
| PCVX | SELL | 2024-09-05 | $538K | — | Filing → |